Bicycle Therapeutics posts Q3 results and gains FDA rare-disease status
+1 new source since this summary was written
Bicycle Therapeutics reported third-quarter 2026 revenue of $34.06M and a net loss of $10.48M, compared with a $59.1M loss a year earlier. In September, U.S. regulators granted nuzefatide pevedotin a rare-disease designation for pancreatic cancer. The company projects its available cash will support operations through 2030 and plans to start a company-sponsored BT1702 radioligand trial in the second half of 2027.
Why it matters
The FDA status may provide development incentives and potential market exclusivity if the treatment is ultimately approved. Bicycle Therapeutics' $469.9M cash balance and management's stated 2030 funding outlook frame its near-term financing needs, while the planned 2027 trial is a future pipeline milestone.
Key facts
- 1Revenue for Q3 2026 was $34.06M, while net loss was $10.48M. tradingview.com
- 2Cash and cash equivalents totaled $469.9 million on September 30, 2026. investing.com
- 3The FDA gave nuzefatide pevedotin Orphan Drug Designation for pancreatic cancer in September. investing.com
- 4Bicycle Therapeutics plans to begin its first company-sponsored radioligand study of BT1702 in the second half of 2027. tradingview.com
Open questions
- The earnings materials give different EPS beat amounts, with one reporting $0.25 and another reporting $0.33.
- The revenue estimate comparison is inconsistent: one material cites expectations of $12.22M, while another reports a $21.86M beat against $34.06M of revenue.
- Year-over-year revenue growth is reported as both 190.2% and 190.4%.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.